Chemoprevention can be defined as the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer. The knowledge of carcinogenic mechanisms provides the scientific rationale for chemoprevention. Epithelial carcinogenesis proceeds through multiple discernible stages of molecular and cellular alterations. Understanding of the multistep nature of carcinogenesis has evolved through highly controlled animal carcinogenesis studies, and these studies have identified three distinct phases: initiation, promotion and progression. Animal model studies have provided evidence that the development of cancer involves many different factors, including alterations in the structures and functions of different genes. Transitions between successive stages can be enhanced or inhibited in the laboratory by different types of agents, such activities providing the fundamental basis for chemoprevention.
References
1.
VogelV.G., LevinB.Chemoprevention of human cancer -an overview. Cancer Bull1995; 47: 473–9.
2.
KhuriF.R., LippmanS.M., SpitzM.R., LotanR., HongW.K.Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst1997; 89: 199–209.
3.
HongW.K., LippmanS.M., ItriL.M.. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. New Engl J Med1990; 323: 795–801.
4.
BollaM., LefurR., Ton VanJ.. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer1994; 30A: 767–72.
5.
TomaS., BonelliL., SartorisA., CortesinaG., MiraE.Beta-carotene and 13cRA in head and neck cancer patients: results of two randomized studies. Proc ASCO2001; 20: 922 (abstract).
6.
BennerS.E., PajakT.F., LippmanS.M., EarlyC., HongW.K.Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst1994; 86: 140–1.
7.
EckhardtK., SchmittG.A retinoic acid receptor alpha antagonist counteracts retinoid teratogenicity in vitro and reduces incidence and/or severity of malformations in vivo. Toxicol Lett1994; 70: 299–308.
8.
TomaS., IsnardiL., RiccardiL., BollagW.Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res1998; 18: 935–42.
9.
IsnardiL., RaffoP., EmioniteL., ChardraratnaR.A.S., TomaS.Different effects of the treatment with AGN 193836 and 9-cis-retinoic acid in breast cancer cells. Anticancer Res1999; 19: 3083–92.
10.
RaffoP., EmioniteL., ColucciL.. Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res2000; 20: 1535–44.
11.
TomaS., RaffoP., NicolòG.. Biological activity of alltrans-retinoic with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Int J Oncol2000; 17: 991–1000.
12.
LotanR.Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst1995; 87: 1655–7.
13.
LippmanS.M., ShinD.M., LeeJ.J.. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res1995; 55: 16–9.
14.
ShackeT., Klehr WirthD., YoshidaM., BeppuT., BodeJ.Gene expression within chromatin domain: the role of core histone hyperacetylation. Biochemistry1994; 33: 4197–206.
15.
GavazzoP., VerganiL., MascettiG.C., NicoliniC.Effects of histone acetylation on chromatin structure. J Cell Biochem1997; 64: 466–75.
16.
RothS.Y., AllisC.D.Histone acetylation and chromatin assembly: a single escort, multiple dances?Cell1996; 87: 5–8.
17.
LibertiniL.J., AusioJ., van HoldeK.E., SmallE.W.Histone hyperacetylation. Its effects on nucleosome core particle transition. Biophys J1988; 53: 477–87.
18.
BauerW.R., HayesJ.J., WhiteJ.H., WolffeA.P.Nucleosome structural changes due to acetylation. J Mol Biol1994; 236: 685–90.
19.
VerganiL., GavazzoP., MascettiG., NicoliniC.Ethidium bromide intercalation and chromatin structure: a spectropolarimetric analysis. Biochemistry1994; 33: 6578–85.
20.
Van HoldeK.E.Chromatin structure.New York: Springer Verlag, 1989.
21.
WolffeA.Chromatin structure and function.London: Academic Press Inc, 1994.
22.
MascettiG., VerganiL., DiasproA., CarraraS., RadicchiG., NicoliniC.Effect of fixatives on calf thymocytes chromatin as analyzed by 3D high-resolution fluorescence microscopy. Cytometry1996; 23: 110–9.
23.
GavazzoP., VerganiL., MascettiG., NicoliniC.Effects of histone acetylation on higher order chromatin structure and function. J Cell Biochem1997; 64: 466–75.
24.
AnnunziatoA., FradoL., SealeR., WoodcockC.Treatment with sodium butyrate inhibits the complete condensation of interphase chromatin. Chromosoma1988; 96: 132–8.
25.
BoffaL.C., MarianiM.R., ParkerM.I.Selective hypermethylation of transcribed nucleosomal DNA by sodium butyrate. Exp Cell Res1994; 211: 420–3.
26.
NanX., NgH.N., JohnsonC.A.. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature1998; 393: 386–9.
27.
SirchiaS.M., FergusonA.T., SironiE.. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor b2 promoter in breast cancer cells. Oncogene2000; 19: 1556–63.
28.
WarrelR.P., Li-ZhenHeJr., RichonV., CallejaE., PandolfiP.P.Therapeutic targeting of transcription in acute promyelocytic leukaemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst1998; 90: 1621–5.
29.
VirmaniA.K., RathiA., Zochbauer-MullerS.. Promoter methylation and silencing of the retinoic acid receptor-b gene in lung carcinomas. J Natl Cancer Inst2000; 92: 1303–7.
SirchiaS.M., RenM., PiliR.. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res2002; 62: 2455–61.
32.
ZengQ., SmithD.C., SuscovichT.J., GoodingW.E., TrumpD.L., GrandisJR. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res2000; 6: 2245–51.
